[Congressional Bills  113th Congress] [From the U.S. Government Printing Office] [S. 2862 Introduced in Senate (IS)] 113th CONGRESS   2d Session                                 S. 2862 To amend the Controlled Substances Act with respect to drug scheduling  recommendations by the Secretary of Health and Human Services, and with   respect to registration of manufacturers and distributors seeking to             conduct clinical testing, and for other purposes. _______________________________________________________________________                    IN THE SENATE OF THE UNITED STATES                            September 18, 2014   Mr. Hatch (for himself and Mr. Whitehouse) introduced the following    bill; which was read twice and referred to the Committee on Health,                       Education, Labor, and Pensions _______________________________________________________________________                                  A BILL   To amend the Controlled Substances Act with respect to drug scheduling  recommendations by the Secretary of Health and Human Services, and with   respect to registration of manufacturers and distributors seeking to             conduct clinical testing, and for other purposes.     Be it enacted by the Senate and House of Representatives of the  United States of America in Congress assembled, SECTION 1. SHORT TITLE.     This Act may be cited as the ``Regulatory Transparency, Patient  Access, and Effective Drug Enforcement Act of 2014. SEC. 2. SCHEDULING OF SUBSTANCES INCLUDED IN NEW FDA-APPROVED DRUGS.     Section 201 of the Controlled Substances Act (21 U.S.C. 811) is  amended by inserting after subsection (h) the following:     ``(i) Within 45 days of receiving a recommendation from the  Secretary to add a drug or substance that has never been marketed in  the United States to a schedule under this title, the Attorney General  shall, without regard to the findings required by subsection (a) of  this section or section 202(b), issue an interim final rule, under the  exception for good cause described in subparagraph (B) of section  553(b) of title 5, United States Code, placing the drug or substance  into the schedule recommended by the Secretary. The interim final rule  shall be made immediately effective under section 553(d)(3) of title 5,  United States Code.. SEC. 3. ENHANCING NEW DRUG DEVELOPMENT.     Section 302 of the Controlled Substances Act (21 U.S.C. 822) is  amended by inserting after subsection (g) the following:     ``(h)(1) A person who submits an application for registration to  manufacture or distribute a controlled substance in accordance with  this section may indicate on the registration application that the  substance will be used only in connection with clinical trials of a  drug in accordance with section 505(i) of the Federal Food, Drug, and  Cosmetic Act.     ``(2) When an application for registration to manufacture or  distribute a controlled substance includes an indication that the  controlled substance will be used only in connection with clinical  trials of a drug in accordance with section 505(i) of the Federal Food,  Drug, and Cosmetic Act, the Attorney General shall--             ``(A) make a final decision on the application for          registration within 180 days; or             ``(B) provide notice to the applicant in writing of--                     ``(i) the outstanding issues that must be resolved                  in order to reach a final decision on the application;                  and                     ``(ii) the estimated date on which a final decision                  on the application will be made.. SEC. 4. REGISTRATION PROCESS UNDER CONTROLLED SUBSTANCES ACT.     (a) Definitions.--             (1) Factors as may be relevant to and consistent with the          public health and safety.--Section 303 of the Controlled          Substances Act (21 U.S.C. 823) is amended by adding at the end          the following:     ``(i) In this section, the phrase `factors as may be relevant to  and consistent with the public health and safety means factors that are relevant to and consistent with the findings contained in section 101.'.            (2) Imminent danger to the public health or safety.--        Section 304(d) of the Controlled Substances Act (21 U.S.C.         824(d)) is amended--                    (A) by striking ``(d) The Attorney General' and                 inserting ``(d)(1) The Attorney General'; and                    (B) by adding at the end the following:    ``(2) In this subsection, the phrase `imminent danger to the public health or safety means that, in the absence of an immediate suspension  order, controlled substances will continue to be distributed or  dispensed by a registrant who knows or should know through fulfilling  the obligations of the registrant under this Act, or has reason to  believe that--             ``(A) the dispensing is outside the usual course of          professional practice;             ``(B) the distribution or dispensing poses a present or          foreseeable risk of adverse health consequences or death due to          the abuse or misuse of the controlled substances; or             ``(C) the controlled substances will continue to be          diverted outside of legitimate distribution channels..     (b) Opportunity To Submit Corrective Action Plan Prior to  Revocation or Suspension.--Subsection (c) of section 304 of the  Controlled Substances Act (21 U.S.C. 824) is amended--             (1) by striking the last two sentences;             (2) by striking ``(c) Before and inserting ``(c)(1)          Before; and             (3) by adding at the end the following:     ``(2) An order to show cause under paragraph (1) shall--             ``(A) contain a statement of the basis for the denial,          revocation, or suspension, including specific citations to any          laws or regulations alleged to be violated by the applicant or          registrant;             ``(B) direct the applicant or registrant to appear before          the Attorney General at a time and place stated in the order,          but not less than 30 days after the date of receipt of the          order; and             ``(C) notify the applicant or registrant of the opportunity          to submit a corrective action plan on or before the date of          appearance.     ``(3) Upon review of any corrective action plan submitted by an  applicant or registrant pursuant to paragraph (2), the Attorney General  shall determine whether denial, revocation or suspension proceedings  should be discontinued, or deferred for the purposes of modification,  amendment, or clarification to such plan.     ``(4) Proceedings to deny, revoke, or suspend shall be conducted  pursuant to this section in accordance with subchapter II of chapter 5  of title 5, United States Code. Such proceedings shall be independent  of, and not in lieu of, criminal prosecutions or other proceedings  under this title or any other law of the United States.     ``(5) The requirements of this subsection shall not apply to the  issuance of an immediate suspension order under subsection (d).. SEC. 5. REPORT TO CONGRESS ON EFFECTS OF LAW ENFORCEMENT ACTIVITIES ON                PATIENT ACCESS TO MEDICATIONS.     (a) In General.--Not later than 1 year after the date of enactment  of this Act, the Secretary of Health and Human Services, acting through  the Commissioner of Food and Drugs and the Director of the Centers for  Disease Control and Prevention, and in consultation with the  Administrator of the Drug Enforcement Administration and the Director  of National Drug Control Policy, shall submit a report to the  Committees on the Judiciary of the House of Representatives, the  Committee on Energy and Commerce of the House of Representatives, the  Committee on the Judiciary of the Senate, and the Committee on Health,  Education, Labor and Pensions of the Senate identifying--             (1) obstacles to legitimate patient access to controlled          substances;             (2) issues with diversion of controlled substances; and             (3) how collaboration between Federal, State, local, and          tribal law enforcement agencies and the pharmaceutical industry          can benefit patients and prevent diversion and abuse of          controlled substances.     (b) Consultation.--The report under subsection (a) shall  incorporate feedback and recommendations from the following:             (1) Patient groups.             (2) Pharmacies.             (3) Drug manufacturers.             (4) Common or contract carriers and warehousemen.             (5) Hospitals, physicians, and other health care providers.             (6) State attorneys general.             (7) Federal, State, local, and tribal law enforcement          agencies.             (8) Health insurance providers and entities that provide          pharmacy benefit management services on behalf of a health          insurance provider.             (9) Wholesale drug distributors.                                  &lt;all&gt; 
